Variation of Serum Prostate-Specific Antigen Levels

Authors:
  • ERElyn Riedel
    Elyn Riedel
  • PSPeter T. Scardino
    Peter T. Scardino
  • MSMoshe Shike
    Moshe Shike
  • MFMartin Fleisher
    Martin Fleisher
  • ASArthur Schatzkin
    Arthur Schatzkin
  • ELElaine Lanza
    Elaine Lanza
  • LLLianne Latkany
    Lianne Latkany
  • CBColin B. Begg
    Colin B. Begg
  • FGfor the Polyp Prevention Trial Study Group
    for the Polyp Prevention Trial Study Group

Abstract
Measurements of serum prostate-specific antigen (PSA) levels in combination with digital rectal examination have long been recommended as part of an early detection program for prostate cancer.1,2 Epidemiological data demonstrate a marked increase in the number of men diagnosed as having prostate cancer and a shift toward earlier-stage disease.3-5 While many of these men are diagnosed as having localized and therefore potentially curable tumors, there has also been a substantial increase in the number of men undergoing radical prostatectomy for small cancers that may be clinically insignificant. Epstein et al6 reviewed 157 men undergoing radical prostatectomy for clinical stage Tlc prostate cancer. Using a definition of insignificant cancer as a pathologically confined tumor with no Gleason component of 4 or 5, and a total tumor volume of less than 0.5 cm3, these investigators found that 26% of their study population had insignificant disease. Similarly, Ohori et al7 reported that 17% of men undergoing radical prostatectomy met the above definition for an insignificant tumor. These data suggest that while widespread use of PSA testing has resulted in the detection of earlier-stage cancers, many of these tumors were unlikely to be a threat to the overall health of the individual.

This publication has 17 references indexed in Scilit: